{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"VOR","limit":50},"count":50,"signals":[{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"restructuring","strength":100,"match_count":28,"context":"nts and marketable securities, together with the expected proceeds from our 2026 Private Placement, will enable us to fund our operating expenses and capital expenditure requirements into early 2029. Restructuring Plan On May 5, 2025, our board of directors approved the wind down of our then-existing clinical and manufacturing operations focused on previous product candidates (the Restructuring Plan). We publicly a","filed_date":"2026-03-30","accession":"0001193125-26-130451","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ming, progress and results of our clinical trials of our product candidate and clinical trials for any future product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2026-03-30","accession":"0001193125-26-130451","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":89,"context":"h would harm our business. Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business. 3 PART I Item 1. Business. ## Overview Vor Biopharma, Inc. (\"Vor Bio\") is a clinical-stage biopharmaceutical company focused on developing a novel therapy in the treatment of autoim","filed_date":"2026-03-30","accession":"0001193125-26-130451","full_text":"https://origin.rootz.global/static/filing/0001193125-26-130451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":30,"context":"201d; has the meaning set forth in Section 3.30. “Licenses” has the meaning set forth in Section 3.21. “Lock-up Period” has the meaning set forth in Section 5.10. “Material Adverse Effect” means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a) was, is, or would reasonably be expected to be, materially adve","filed_date":"2026-03-27","accession":"0001193125-26-127609","full_text":"https://origin.rootz.global/static/filing/0001193125-26-127609.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"restructuring","strength":100,"match_count":23,"context":"expense) on the condensed consolidated statement of operations and comprehensive loss. As of September 30, 2025, the Company has both equity-classified and liability-classified warrants outstanding. Restructuring Costs Employee severance costs are recorded based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on","filed_date":"2025-11-13","accession":"0001193125-25-280104","full_text":"https://origin.rootz.global/static/filing/0001193125-25-280104.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"nd results of our clinical trials of our product candidate and preclinical and clinical trials for any future product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2025-11-13","accession":"0001193125-25-280104","full_text":"https://origin.rootz.global/static/filing/0001193125-25-280104.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":41,"context":"uld harm our business. iii Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business. iv PART IFINANCIAL INFORMATION Item 1. Financial Statements (Unaudited). VOR BIOPHARMA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | | | | | September 30, | | |","filed_date":"2025-11-13","accession":"0001193125-25-280104","full_text":"https://origin.rootz.global/static/filing/0001193125-25-280104.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":22,"context":"i) the issuance, if any, of stock upon conversion of Company securities as described in the Pricing Prospectus and the Prospectus) or long‑term debt of the Company or its subsidiary or (y) any Material Adverse Effect (as defined below); as used in this Agreement, “Material Adverse Effect” shall mean any material adverse change or effect, or any development involving a prospective material adverse ch","filed_date":"2025-11-12","accession":"0001193125-25-275862","full_text":"https://origin.rootz.global/static/filing/0001193125-25-275862.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pant holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2025-08-27","accession":"0001193125-25-189169","full_text":"https://origin.rootz.global/static/filing/0001193125-25-189169.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"restructuring","strength":100,"match_count":20,"context":"ome (expense) on the condensed consolidated statement of operations and comprehensive loss. As of June 30, 2025, the Company has both equity-classified and liability-classified warrants outstanding. Restructuring Costs Employee severance costs are recorded based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on","filed_date":"2025-08-12","accession":"0000950170-25-107276","full_text":"https://origin.rootz.global/static/filing/0000950170-25-107276.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"nd results of our clinical trials of our product candidate and preclinical and clinical trials for any future product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2025-08-12","accession":"0000950170-25-107276","full_text":"https://origin.rootz.global/static/filing/0000950170-25-107276.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":44,"context":"uld harm our business. iii Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business. iv PART IFINANCIAL INFORMATION Item 1. Financial Statements (Unaudited). VOR BIOPHARMA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | | | | | June 30, | | | Decem","filed_date":"2025-08-12","accession":"0000950170-25-107276","full_text":"https://origin.rootz.global/static/filing/0000950170-25-107276.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":40,"context":"D OF DIRECTORS RECOMMENDS A VOTE FOR THE APPROVAL OF THE AMENDMENT OF THE AMENDED AND RESTATED VOR BIOPHARMA INC. 2021 EQUITY INCENTIVE PLAN 25 [TABLE OF CONTENTS](#TOC) EXECUTIVE COMPENSATION Our named executive officers for the year ended December31, 2024 consist of: | | Dr. Robert Ang, our former principal executive officer, President and Chief Executive Officer; | | | | Dr. Eyal Attar, our former Chief Medical O","filed_date":"2025-08-08","accession":"0001140361-25-029749","full_text":"https://origin.rootz.global/static/filing/0001140361-25-029749.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":27,"context":"our Common Stock, as of March1, 2025, by: | | | | each person known by us to beneficially own more than 5% of our Common Stock; | | | | | | each of our directors; | | | | | | each of our named executive officers; and | | | | | | all of our executive officers and directors as a group. | | The column entitled Percentage of Shares Beneficially Owned is based on a total of 124,849,134 shares of our Common S","filed_date":"2025-04-08","accession":"0001193125-25-075715","full_text":"https://origin.rootz.global/static/filing/0001193125-25-075715.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ion, statements about: the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2025-03-20","accession":"0000950170-25-042623","full_text":"https://origin.rootz.global/static/filing/0000950170-25-042623.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":87,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval, even if these side effects or characteristics are unrelated to our product candidate. We face significant competition in an environment of rapid technolog","filed_date":"2025-03-20","accession":"0000950170-25-042623","full_text":"https://origin.rootz.global/static/filing/0000950170-25-042623.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pant holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2024-05-28","accession":"0001193125-24-148151","full_text":"https://origin.rootz.global/static/filing/0001193125-24-148151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"f our Common Stock on the grant date, and is scheduled to vest over four years, with 25% of the shares scheduled to vest on October 11, 2023, and the remainder scheduled to vest in equal monthly installments thereafter through October 11, 2026, subject to such Dr. Attars continued service with us through the applicable vesting dates. | | **Certain Interests of Directors** In considering the recommend","filed_date":"2024-04-09","accession":"0001193125-24-090781","full_text":"https://origin.rootz.global/static/filing/0001193125-24-090781.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":40,"context":"r Common Stock, as of March 26, 2024, by: | | | | each person known by us to beneficially own more than 5% of our Common Stock; | | | | | | each of our directors; | | | | | | each of our named executive officers; and | | | | | | all of our executive officers and directors as a group. | | The column entitled Percentage of Shares Beneficially Owned is based on a total of 68,215,771 shares of our Common St","filed_date":"2024-04-09","accession":"0001193125-24-090781","full_text":"https://origin.rootz.global/static/filing/0001193125-24-090781.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ion, statements about: the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2024-03-20","accession":"0000950170-24-034146","full_text":"https://origin.rootz.global/static/filing/0000950170-24-034146.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":80,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval, even if these side effects or characteristics are unrelated to our product candidate. We face significant competition in an environment of rapid technolog","filed_date":"2024-03-20","accession":"0000950170-24-034146","full_text":"https://origin.rootz.global/static/filing/0000950170-24-034146.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"tions granted to Dr. Ang on August 5, 2019 and are subject to our right of repurchase upon Dr. Angs termination of service. The shares will be released from our repurchase right in equal monthly installments on the fifth day of each month through August 5, 2023, subject to continuous service with us as of each such date. The restricted shares are subject to vesting acceleration, as described in more","filed_date":"2023-04-14","accession":"0001193125-23-102025","full_text":"https://origin.rootz.global/static/filing/0001193125-23-102025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"ur Common Stock, as of April 3, 2023, by: | | | | each person known by us to beneficially own more than 5% of our Common Stock; | | | | | | each of our directors; | | | | | | each of our named executive officers; and | | | | | | all of our executive officers and directors as a group. | | The column entitled Percentage of Shares Beneficially Owned is based on a total of 66,934,898 shares of our Common St","filed_date":"2023-04-14","accession":"0001193125-23-102025","full_text":"https://origin.rootz.global/static/filing/0001193125-23-102025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"ements about: • the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2023-03-23","accession":"0000950170-23-009472","full_text":"https://origin.rootz.global/static/filing/0000950170-23-009472.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":38,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval, even if these side effects or characteristics are unrelated to our product candidate. • We face significant competition in an environment of rapid","filed_date":"2023-03-23","accession":"0000950170-23-009472","full_text":"https://origin.rootz.global/static/filing/0000950170-23-009472.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":17,"context":"pursuant to the Registration Statement or otherwise registered by the Company under the Act except as have been validly waived or complied with in connection with the offering of the Shares. (k) No Material Adverse Effect. Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus:","filed_date":"2022-12-23","accession":"0001193125-22-311777","full_text":"https://origin.rootz.global/static/filing/0001193125-22-311777.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ion, statements about: • the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; • the ti","filed_date":"2022-05-12","accession":"0000950170-22-009649","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009649.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":39,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. • We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regu","filed_date":"2022-05-12","accession":"0000950170-22-009649","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009649.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":22,"context":"of our Common Stock, as of April 18, 2022: | | | | Each person known by us to beneficially own more than 5% of our Common Stock; | | | | | | each of our directors; | | | | | | each of our named executive officers; and | | | | | | all of our executive officers and directors as a group. | | The column entitled Percentage of Shares Beneficially Owned is based on a total of 37,511,434 shares of our Common St","filed_date":"2022-04-28","accession":"0001193125-22-125555","full_text":"https://origin.rootz.global/static/filing/0001193125-22-125555.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":29,"context":"ion, statements about: • the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; • the ti","filed_date":"2022-03-14","accession":"0000950170-22-003577","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003577.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. • We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regu","filed_date":"2022-03-14","accession":"0000950170-22-003577","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003577.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"l written submissions received from stockholders that include the information described above will be reviewed by the committee at its next appropriate meeting. Item 11. Executive Compensation. Our named executive officers for the year ended December 31, 2021 consist of our principal executive officer, Robert Ang, our President and Chief Executive Officer, and our next two most highly compensated executive officers Dr","filed_date":"2022-03-14","accession":"0000950170-22-003577","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003577.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ion, statements about:  the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;  the ti","filed_date":"2021-11-10","accession":"0000950170-21-004072","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":38,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval.  We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regu","filed_date":"2021-11-10","accession":"0000950170-21-004072","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ion, statements about: | | | the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs | | | | | the","filed_date":"2021-08-09","accession":"0001564590-21-042607","full_text":"https://origin.rootz.global/static/filing/0001564590-21-042607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":38,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. | | | | | We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve","filed_date":"2021-08-09","accession":"0001564590-21-042607","full_text":"https://origin.rootz.global/static/filing/0001564590-21-042607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"lines and plans remains uncertain and will depend on certain developments, including the duration and subsequent waves, including any variants of the outbreak and its impact on our clinical trial enrollment, trial sites, contract research organizations (CROs), third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scien","filed_date":"2021-05-06","accession":"0001564590-21-024936","full_text":"https://origin.rootz.global/static/filing/0001564590-21-024936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":38,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. | | | | | We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve","filed_date":"2021-05-06","accession":"0001564590-21-024936","full_text":"https://origin.rootz.global/static/filing/0001564590-21-024936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"delays into our current clinical development timeline, including delays in initiating our first-in-human clinical trial of VOR33. Additional results from this third party trial may also result in enrollment delays. We continue to expect to use CD34 enrichment in manufacturing VOR33 but we are evaluating the potential development of T-cell replete eHSCs if necessary, to address concerns among stakehol","filed_date":"2021-03-25","accession":"0001564590-21-015474","full_text":"https://origin.rootz.global/static/filing/0001564590-21-015474.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. | | | | • | We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may","filed_date":"2021-03-25","accession":"0001564590-21-015474","full_text":"https://origin.rootz.global/static/filing/0001564590-21-015474.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"l written submissions received from stockholders that include the information described above will be reviewed by the committee at its next appropriate meeting. Item 11. Executive Compensation. Our named executive officers for the year ended December31, 2020 consist of our principal executive officer, Robert Ang, our President and Chief Executive Officer, and our next two most highly compensated executive officers Dr.","filed_date":"2021-03-25","accession":"0001564590-21-015474","full_text":"https://origin.rootz.global/static/filing/0001564590-21-015474.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":33,"context":"s, either as a result of the timely transfer to us by the NMDP of the related IND or obtaining cross-reference rights to those trial results; | | | | | | the initiation and successful patient enrollment and completion of additional clinical trials of VOR33 and VCAR33 on a timely basis; | | | | | | maintaining and establishing relationships with contract research organizations (CROs) and clini","filed_date":"2021-02-03","accession":"0001193125-21-026728","full_text":"https://origin.rootz.global/static/filing/0001193125-21-026728.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":44,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. | | | | | | We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achie","filed_date":"2021-02-03","accession":"0001193125-21-026728","full_text":"https://origin.rootz.global/static/filing/0001193125-21-026728.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"on concerning certain of the specific assumptions we used in valuing options. | | | (2) | The table below shows the aggregate number equity awards outstanding for each of our directors who is not a named executive officer, as of December 31, 2020. | | | | | | | | | | | | | | Name | | Number ofOutstandingOptions | | | Number ofOutstandingUnvestedStockAwards | | | | Kush Parmar, M.D., Ph.D. | | | |","filed_date":"2021-02-03","accession":"0001193125-21-026728","full_text":"https://origin.rootz.global/static/filing/0001193125-21-026728.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"s, either as a result of the timely transfer to us by the NMDP of the related IND or obtaining cross-reference rights to those trial results; | | | | | | the initiation and successful patient enrollment and completion of additional clinical trials of VOR33 and VCAR33 on a timely basis; | | | | | | maintaining and establishing relationships with contract research organizations (CROs) and clini","filed_date":"2021-01-15","accession":"0001193125-21-010219","full_text":"https://origin.rootz.global/static/filing/0001193125-21-010219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":43,"context":"effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval. | | | | | | We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achie","filed_date":"2021-01-15","accession":"0001193125-21-010219","full_text":"https://origin.rootz.global/static/filing/0001193125-21-010219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"on concerning certain of the specific assumptions we used in valuing options. | | | (2) | The table below shows the aggregate number equity awards outstanding for each of our directors who is not a named executive officer, as of December 31, 2020. | | | | | | | | | | | | | | Name | | Number ofOutstandingOptions | | | Number ofOutstandingUnvestedStockAwards | | | | Kush Parmar, M.D., Ph.D. | | | |","filed_date":"2021-01-15","accession":"0001193125-21-010219","full_text":"https://origin.rootz.global/static/filing/0001193125-21-010219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"ements about: the timing, progress and results of our clinical trials of our product candidate and any future product candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our research and development pro","filed_date":"2026-08-11","accession":"0001193125-26-343607","full_text":"https://origin.rootz.global/static/filing/0001193125-26-343607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":47,"context":"h would harm our business. Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business. iv PART IFINANCIAL INFORMATION Item 1. Financial Statements (Unaudited). VOR BIOPHARMA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | | | | | June 30, | | | Decem","filed_date":"2026-08-11","accession":"0001193125-26-343607","full_text":"https://origin.rootz.global/static/filing/0001193125-26-343607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VOR","company":"Vor Biopharma Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"of our common stock on the grant date, and is scheduled to vest over four years, with 25% of the shares scheduled to vest on October11, 2023, and the remainder scheduled to vest in equal monthly installments thereafter through October11, 2026, subject to such Dr.Attars continued service with us through the applicable vesting dates. Dr.Attar resigned as the Companys Chief Medical Officer, effective as","filed_date":"2025-08-08","accession":"0001140361-25-029749","full_text":"https://origin.rootz.global/static/filing/0001140361-25-029749.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"1dfbc1f023e8f48a1a6a244ce23358d886f25f6f1a58e122b3cbe02f5a7ac051","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"1e2cfcdeda6622841fdae4d572b88e24356a4956235537f414cccc552042d38b","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":120,"hourly_limit":500,"remaining":380,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}